Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD30 + status confers therapeutic sensitivity to Brentuximab Vedotin in patients with Hodgkin Lymphoma.
The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkins Lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
This statement is based on a regulatory approval from the Health Service Executive:
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option